Alizadeh
Arash Ash Alizadeh, San Mateo, CA US
Patent application number | Description | Published |
---|---|---|
20120134986 | Methods of Prognosis for Non-Hodgkin Lymphoma - Measurement of a single gene expressed by tumor cells (LMO2) and a single gene expressed by the immune microenvironment (TNFRSF9), which determination may be referred to herein as a two gene score (TGS), powerfully predicts overall survival in patients with NHL, particularly overall survival in the context of anthracycline-based chemotherapy or co-treatment with anthracycline-based chemotherapy and anti-CD20 immunotherapy. It is shown herein that increased levels of LMO2 and TNFRSF9 correlate with a positive patient response and improved prognosis. | 05-31-2012 |
20120282174 | Synergistic Anti-CD47 Therapy for Hematologic Cancers - Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2. | 11-08-2012 |
20120321646 | Methods for Enhancing Anti-Tumor Antibody Therapy - Methods of enhancing the efficacy of antibody-directed cellular cytotoxicity (ADCC) for therapy directed to killing of tumor cells are disclosed. Cancer specific cell surface antigens are bound by monoclonal antibodies, thereby stimulating a cytotoxic T cell response characterized by an upregulation of cell surface expression of costimulatory molecules on the T cell. The ADCC response is augmented by the subsequent administration of a second antibody that is an agonist of the costimulatory molecule. | 12-20-2012 |
20140148351 | Prediction of Clinical Outcome in Hematological Malignancies Using a Self-Renewal Expression Signature - Methods, compositions, and kits are provided for providing a diagnosis, a prognosis, or a prediction of responsiveness to a therapy for a patient with a hematological malignancy. In practicing the subject methods, the expression level of at least one leukemia stem cell (LSC) genes in a tissue sample is assayed to obtain an LSC expression representation. The LSC expression representation is then employed to determine if an individual has a hematological malignancy, to provide a prognosis to a patient with a hematological malignancy, and/or to provide a prediction of the responsiveness of a patient with a hematological malignancy to a therapy. Also provided are screening methods for identifying novel therapies for patients with a hematological malignancy, and compositions and kits for use in these screening methods. | 05-29-2014 |
20140220562 | Method of Predicting Responsiveness of B Cell Lineage Malignancies to Active Immunotherapy - Predictive biomarkers identify those patients suffering from immunoglobulin positive (Ig | 08-07-2014 |
20140296081 | IDENTIFICATION AND USE OF CIRCULATING TUMOR MARKERS - Methods for creating a library of recurrently mutated genomic regions and for using the library to analyze cancer-specific and patient-specific genetic alterations in a patient are provided. The methods can be used to measure tumor-derived nucleic acids in patient blood and thus to monitor the progression of disease. The methods can also be used for cancer screening. | 10-02-2014 |
20140369924 | SYNERGISTIC ANTI-CD47 THERAPY FOR HEMATOLOGIC CANCERS - Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2. | 12-18-2014 |
Ash A. Alizadeh, San Mateo, CA US
Patent application number | Description | Published |
---|---|---|
20100143926 | Classification of Patients Having Diffuse Large B-cell Lymphoma Based upon Gene Expression - Methods and kits for classifying patients having diffuse large B-cell lymphoma (DLBCL) based upon expression of a plurality of genes are disclosed. Real-time quantitative RT-PCR can be used to measure expression values. Correlating expression values of the plurality of genes in a tumor sample from the patient to reference expression values obtained from DLBCL patients can stratify patients in the classification groups. The methods and kits can be used to predict overall patient survival. | 06-10-2010 |
Azar Alizadeh, Wilton, NY US
Patent application number | Description | Published |
---|---|---|
20100147762 | MEMBRANE ASSEMBLIES AND METHODS OF MAKING AND USING THE SAME - A method of making a membrane assembly is provided. The method comprises forming an inorganic membrane layer disposed on a substrate, and forming a plurality of macropores in the substrate at least in part using anodization. Further, a membrane assembly is provided. The membrane assembly comprises a filtering membrane that is coupled to an anodized substrate comprising a plurality of macropores. | 06-17-2010 |
Bahram Alizadeh, Maidstone GB
Patent application number | Description | Published |
---|---|---|
20150268095 | Method and System for Correcting Incident Light Fluctuations in Absorption Spectroscopy - A method and system for correcting the effect of intensity fluctuations of the transmitted light in an absorption spectroscopy system used for the detection or measurement of chemical species in a medium, whereby one or more modulation bursts are imposed onto a light beam that passes through the medium. This burst signal may be obtained by modulating the bias current of a tunable diode laser, and the modulation burst signal may be optimally at the second harmonic of the modulation frequency of a wavelength modulated beam to allow usage of the same signal path processing used for the spectroscopic detection of the measurand for a second harmonic detection system. The burst signal can be controlled using a smooth window function to minimise the effects of non-linear perturbations that are inherent in tunable diode laser wavelength modulation spectroscopy systems, of optical interference fringes (etalons) and of the residual light absorption by background chemical species or the measurand at the wavelength coinciding with the modulation burst. | 09-24-2015 |
Bahram Alizadeh, Madistone GB
Patent application number | Description | Published |
---|---|---|
20110296910 | THERMAL FLUID FLOW APPARATUS - Provided is a compact apparatus for measuring the flow rate of a fluid. The apparatus includes a heated measure element and a heated reference element which are in substantially the same thermal environment within a measure cell, except that the measure element is situated in the path of the cooling fluid flow and the reference element is sheltered from this direct fluid flow. These elements are arranged as parallel and concentric planar elements that are essentially identical to each other with matching thermal characteristics. The elements are electrically connected in a Wheatstone bridge arrangement. Thermal exchange between the reference and measure elements is used to optimise noise rejection due to common mode background thermal effects. Measured parameters from the bridge can be used to derive the fluid flow rate. | 12-08-2011 |
Darya Alizadeh, Mission Viejo, CA US
Patent application number | Description | Published |
---|---|---|
20130210896 | Immunotheraphy of Brain Tumors Using a Nanoparticle CpG Delivery System - One aspect of the invention relates to a nanoparticle conjugated CpG (NANO-CpG) composition and pharmaceutical composition thereof, and the preparation methods thereof. Another aspect of the invention relates to a method for using the NANO-CpG to improve CpG delivery into brain tumor associated inflammatory cells in a subject. Another aspect of the invention relates to a method for treating or preventing a method for treating and/or preventing a brain tumor in a subject comprising administering a therapeutically effective amount of the NANO-CpG or a pharmaceutical composition thereof to the subject. In one embodiment, a subject treated with the NANO-CpG composition disclosed herein or a pharmaceutical composition thereof developed immunity to brain tumor. | 08-15-2013 |
Jafar Alizadeh, Houston, TX US
Patent application number | Description | Published |
---|---|---|
20130332934 | Task Control in a Computing System - A computing system can include sensor and a task. The sensor can generate sensor data. The computing system can delay the task based on the sensor data. | 12-12-2013 |
Reza Alizadeh, Tehran IR
Patent application number | Description | Published |
---|---|---|
20100000261 | Method for making SPME fiber - It is disclosed a method for making SPME fibers. The SPME fibers consist of metal-oxide coatings on fused-silica fibers. The coatings are prepared from a water-based solution containing a predetermined amount of metal ion and a predetermined amount of a reactant. The water based solution and the fused-silica fibers are kept at the temperatures below 100° C. for a predetermined time to obtain SPME fibers. The SPME fibers are applied for extraction of pesticides and other organic compounds such as 1,4-dichloro-2-nitrobenzene; Biphenyl; and Acenaphthene in the water based solution and cooling gas of a power generator respectively. | 01-07-2010 |
Rouhollah Alizadeh, Gloucester CA
Patent application number | Description | Published |
---|---|---|
20140210494 | ELECTRICAL METHODS AND SYSTEMS FOR CONCRETE TESTING - Hundreds of thousands of concrete bridges and hundreds of billions of tons of concrete require characterization with time for corrosion. Accordingly, protocols for rapid testing and improved field characterization systems that automatically triangulate electrical resistivity and half-cell corrosion potential measurements would be beneficial allowing discrete/periodic mapping of a structure to be performed as well as addressing testing for asphalt covered concrete. Further, it is the low frequency impedance of rebar in concrete that correlates to corrosion state but these are normally time consuming vulnerable to noise. Hence, it would be beneficial to provide a means of making low frequency electrical resistivity measurements rapidly. Further, prior art techniques for electrical rebar measurements require electrical connection be made to the rebar which increases measurement complexity/disruption/repair/cost even when no corrosion is identified. Beneficially a method of determining the state of a rebar without electrical contact is taught. | 07-31-2014 |
Yasser Alizadeh, Portland, OR US
Patent application number | Description | Published |
---|---|---|
20150309283 | AUXILIARY CAMERA LENS - A lens assembly having a housing, an interior cavity, a first lens, and a second lens. The housing includes a reflective surface substantially covering at least a portion of an inner surface of the housing. The interior cavity is substantially surrounded by the inner surface of the tubular housing. The first lens extends across the first end of the housing, and it is configured to receive light from a scene outside of the lens assembly and refract the light into the interior cavity of the lens assembly. The second lens extends across the second end of the tubular housing, and it is configured to receive light from the interior cavity of the lens assembly and refract the light to a region outside of the lens assembly. Related methods are also disclosed. | 10-29-2015 |